Increased Susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability

Clinical Infectious Diseases

Volumn 55, Issue 4, 2012, Pages 534-542

  Buyck, Julien M ^a   Plésiat, Patrick ^b   Traore, H ^c   Vanderbist, F ^c   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c SMB Laboratoires   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; CLARITHROMYCIN DERIVATIVE; ERYTHROMYCIN; NAPHTHALENE DERIVATIVE; NITROCEFIN; OUTER MEMBRANE PROTEIN; PHENYL ARGININE BETA NAPHTHYLAMIDE; QUINOLONE DERIVATIVE; SOLITHROMYCIN; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BODY FLUID; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG UPTAKE; EUKARYOTIC CELL; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; ISOTOPE LABELING; LUNG LAVAGE; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPRM GENE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; SERUM;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL OUTER MEMBRANE PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; CELL MEMBRANE PERMEABILITY; CULTURE MEDIA; DIPEPTIDES; HYDROGEN-ION CONCENTRATION; KETOLIDES; MEMBRANE TRANSPORT PROTEINS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA;

EID: 84864464289     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis473     Document Type: Article

References (33)

1. Mesaros N, Nordmann P, Plesiat P, et al. Pseudomonas aeruginosa: Resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007; 13:560-78.
2. Angus BL, Carey AM, Caron DA, Kropinski AM, Hancock RE. Outer membrane permeability in Pseudomonas aeruginosa: Comparison of a wild-Type with an antibiotic-supersusceptible mutant. Antimicrob Agents Chemother 1982; 21:299-309.
3. Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: Components, mechanisms and clinical significance. Curr Top Med Chem 2001; 1:59-71.
4. Livermore DM, Yang YJ. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against betalactamase- inducibility mutants of Pseudomonas aeruginosa. J Infect Dis 1987; 155:775-82.
5. Performance standards for antimicrobial susceptibility testing. 20th informational supplement (MS100-S20). Wayne, PA: Clinical and Laboratory Standard Institute, 2010.
6. Cai Y, Chai D, Wang R, Bai N, Liang BB, Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: A meta-Analysis and systematic review. J Antimicrob Chemother 2011; 66:968-78.
7. Konstan MW, VanDevanter DR, Rasouliyan L, et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72.
8. Yousef AA, Jaffe A. The role of azithromycin in patients with cystic fibrosis. Paediatr Respir Rev 2010; 11:108-14.
9. Labro MT. Anti-inflammatory activity of macrolides: A new therapeutic potential? J Antimicrob Chemother 1998; 41(Suppl B):37-46.
10. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: A global approach. Antimicrob Agents Chemother 2006; 50:1680-8.
11. Imamura Y, Higashiyama Y, Tomono K, et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob Agents Chemother 2005; 49:1377-80.
12. Nagata T, Mukae H, Kadota J, et al. Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob Agents Chemother 2004; 48:2251-9.
13. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45:105-16.
14. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 2003; 47:2283-92.
15. Kluge RM, Standiford HC, Tatem B, et al. Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1974; 6:442-6.
16. Baussanne I, Bussiere A, Halder S, et al. Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. J Med Chem 2010; 53:119-27.
17. Mesaros N, Glupczynski Y, Avrain L, Caceres NE, Tulkens PM, Van Bambeke F. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 2007; 59:378-86.
18. Wolter DJ, Black JA, Lister PD, Hanson ND. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype. J Antimicrob Chemother 2009; 64:294-300.
19. Helander IM, Mattila-Sandholm T. Fluorometric assessment of gramnegative bacterial permeabilization. J Appl Microbiol 2000; 88:213-9.
20. Loh B, Grant C, Hancock RE. Use of the fluorescent probe 1-Nphenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 26:546-51.
21. Nikaido H. The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access? Drug Resist Updat 1998; 1:93-8.
22. Hancock RE, Raffle VJ, Nicas TI. Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1981; 19:777-85.
23. Runyan CM, Carmen JC, Beckstead BL, Nelson JL, Robison RA, Pitt WG. Low-frequency ultrasound increases outer membrane permeability of Pseudomonas aeruginosa. J Gen Appl Microbiol 2006; 52:295-301.
24. Nakajima K, Kawamata J. Studies on the mechanism of action of colistin. II. Alteration of permeability of Escherichia coli by colistin. Biken J 1965; 8:233-9.
25. Savage PB, Li C, Taotafa U, Ding B, Guan Q. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002; 217:1-7.
26. Stinnett JD, Gilleland HE Jr, Eagon RG. Proteins released from cell envelopes of Pseudomonas aeruginosa on exposure to ethylenediaminetetraacetate: Comparison with dimethylformamide-extractable proteins. J Bacteriol 1973; 114:399-407.
27. Pillai SK, Eliopoulos GM, Moellering RC Jr. Principles of antiinfective therapy. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia, PA; Elsevier, 2010; 267-78.
28. Schweizer HP. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: Unanswered questions. Genet Mol Res 2003; 2:48-62.
29. Maseda H, Yoneyama H, Nakae T. Assignment of the substrateselective subunits of the MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44:658-64.
30. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXYoprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44:3322-7.
31. Tateda K, Ishii Y, Matsumoto T, Kobayashi T, Miyazaki S, Yamaguchi K. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: Suppression of virulence factors and stress response. J Infect Chemother 2000; 6:1-7.
32. Cai H, Rose K, Liang LH, Dunham S, Stover C. Development of a liquid chromatography/mass spectrometry-based drug accumulation assay in Pseudomonas aeruginosa. Anal Biochem 2009; 385: 321-5.
33. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25(Suppl A):73-82.